You are here: Industry Insights > NVX-CoV2373

News List

Novavax and European Commission finalise advance purchase agreement for up to 200 million doses of COVID-19 vaccine expresspharma
August 06, 2021
Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant.
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine prnasia
August 05, 2021
Novavax announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.
Novavax’ COVID-19 vaccine almost 90 percent effective in Phase III trials europeanpharmaceuticalreview
July 02, 2021
In UK trials where 60 percent of COVID-19 cases were caused by the Alpha SARS-CoV-2 variant, the NVX-CoV2373 COVID-19 vaccine was 89.7 percent effective.
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine firstwordpharma
July 01, 2021
Novavax today announced the publication of results from the final analysis of a pivotal Phase 3 clinical trial of its COVID-19 vaccine candidate conducted in the United Kingdom in the New England Journal of Medicine (NEJM).
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre firstwordpharma
June 23, 2021
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry announced today that construction of the new Biologics Manufacturing Centre (BMC) at the National Research Council of Canada's (NRC)’s Royalmount location.
Study demonstrates safety and efficacy of co-administering COVID-19 and flu vaccines pharmatimes
June 18, 2021
A study conducted by Novavax has found that co-administering a COVID-19 vaccine with a flu vaccine is safe and effective, with the efficacy of both jabs appearing to be preserved.
Influenza Vaccine and Novavax COVID-19 Vaccine Simultaneous Administration Yields Positive Results americanpharmaceuticalreview
June 17, 2021
Novavax Inc., a biotechnology company developing next-generation vaccines for serious infectious diseases, announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine ...
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously firstwordpharma
June 15, 2021
Novavax, Inc. today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine [Seqirus, adjuvanted, trivalent seasonal influenza vaccine.
Novavax COVID-19 Vax is 90% Effective in Phase 3 Trial contractpharma
June 15, 2021
NVX-CoV2373 demonstrates 100% protection against moderate and severe disease, 90% efficacy overall, and met the primary endpoint.
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update firstwordpharma
May 25, 2021
NVAX today announced that Gregory M. Glenn, M.D., will present on NVX-CoV2373, the company's recombinant nanoparticle COVID-19 vaccine candidate, during the 2021 International Society for Vaccines Virtual Congress 6thCOVID-19 Vaccine Update.

Previous page 1 2 3 4 5 6 7 Next page